BECLOMETHASONE DIPROPIONATE

/static/temp/default.svg

Search structure


Trade Names	BECLOVENT BECONASE QNASL QVAR 40 QVAR 80 QVAR REDIHALER VANCENASE VANCERIL VANCERIL DOUBLE STRENGTH
Synonyms	Aerobec 100 Aerobec 50 Aerobec fte 250 Asmabec clickhaler Asmabec spacehaler Beclazone 100 Beclazone 100 e-breathe Beclazone 200 Beclazone 250 Beclazone 250 e-breathe Beclazone 50 Beclazone 50 e-breathe Becloaqua 50 Becloforte Becloforte e-breathe Becloforte integra Becloforte-vm Beclomet diprop Beclomet hayfever Beclometasone Beclometasone dipropionate Beclomethasone Beclomethasone dipropionate Beclomethasone dipropionate monohydrate Beclomist Beclotaide Beclovent Becodisks Beconase Beconase aq Becotide Becotide 100 Becotide 100 e-breathe Becotide 200 Becotide 50 Becotide 50 e-breathe Clenil modulite Clipper Filair 100 Filair 50 Filair fte Fostair Fostair nexthaler NSC-755901 Nasobec aq Nasobec hayfever Propaderm Propaderm fte Propaderm-a Propaderm-c Pulvinal beclomet Qnasl Qvar 100 Qvar 100 e-breathe Qvar 40 Qvar 50 Qvar 50 e-breathe Qvar 80 Qvar redihaler Rino clenil SCH 18020W SCH 8020W SCH-18020W SGX-201 SGX-202 SGX-203 Vancenase Vancenase aq Vancenase pockethaler Vanceril Vanceril double strength Ventide Vivabec Zonivent aquanasal
Status
Molecule Category	Free-form
UNII	5B307S63B2
EPA CompTox	DTXSID3048730
Parent Compound:


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	KUVIULQEHSCUHY-XYWKZLDCSA-N
Smiles	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C
InChI	InChI=1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C28H37ClO7
Molecular Weight	521.05
AlogP	4.09
Hydrogen Bond Acceptor	7.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	6.0
Polar Surface Area	106.97
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	36.0

Bioactivity

Mechanism of Action	Action	Reference
Glucocorticoid receptor agonist	AGONIST	DailyMed


Protein: Glucocorticoid receptor Description: Glucocorticoid receptor Organism : Homo sapiens P04150 ENSG00000113580

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	15

Assay Description	Organism	Bioactivity	Reference
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	Cricetulus griseus	41.53 %
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	Cricetulus griseus	14.78 %
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600)	Staphylococcus aureus subsp. aureus	4.92 %
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600)	Escherichia coli	-8.75 %
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600)	Klebsiella pneumoniae	7.24 %
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600)	Pseudomonas aeruginosa	2.46 %
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600	Acinetobacter baumannii	18.55 %
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630	Candida albicans	3.12 %
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570)	Cryptococcus neoformans	1.67 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	1.84 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	8.77 %		SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	14.89 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.06 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.08 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.06 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.08 %

Cross References

Resources	Reference
ChEBI	3002
ChEMBL	CHEMBL1200500
DrugBank	DB00394
DrugCentral	294
FDA SRS	5B307S63B2
Human Metabolome Database	HMDB0014538
Guide to Pharmacology	5894
KEGG	C07813
PubChem	21700
SureChEMBL	SCHEMBL6890
ZINC	ZINC000003938744

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).